This paper examines the ethically problematic relationship between physicians and pharmaceutical companies in the United States. Drawing on peer-reviewed sources from the New England Journal of Medicine and the British Medical Journal, the paper argues that pharmaceutical marketing — through gifts, free meals, sponsored conferences, and research funding — measurably alters doctors' prescribing habits in ways that harm patients. The paper critiques the Affordable Care Act's Sunshine Law as insufficient, highlights the denial among physicians regarding industry influence, and calls for comprehensive legislative reform modeled on conflict-of-interest bans adopted by select academic medical centers. The broader argument situates these conflicts within a for-profit health care system that consistently prioritizes corporate profits over patient welfare.
The paper effectively uses source synthesis to build a cumulative argument. Rather than treating each source in isolation, it layers findings from Moynihan (2003), Campbell (2007), and Carollo (2010) so that each successive citation reinforces and deepens the previous one, moving from evidence of behavioral influence to statistical scale to policy failure. This stacking technique strengthens the argument's overall persuasive weight.
The paper opens with a macro-level critique of the for-profit health care system, narrows to the specific doctor-pharmaceutical relationship, documents its empirical harms and the culture of denial surrounding them, assesses current legislative attempts as inadequate, dismantles pro-industry arguments, and concludes with a concrete reform proposal. This funnel structure — broad systemic critique → specific evidence → policy response — is a reliable model for health policy argumentative writing.
Although the Affordable Care Act represents a step in the right direction toward encouraging all Americans to access medical services, it fails to address the root causes of the system's problems. The American health care system is flawed because it operates as a for-profit model that places financial gain far ahead of patients. When profits take precedence over patients, health care workers become unable to fulfill their ethical duties. A progressive transformation of the American health care system would systematically undo the harmful link between corporate interests and the interests of patient care.
The relationship between doctors and drug companies has been well established and well documented. Major news outlets such as The Atlantic, as well as peer-reviewed journals like the New England Journal of Medicine, have covered the ethical conundrums inherent in the close relationship between physicians and pharmaceutical companies. Shaywitz (2013) described the problem as involving "a bunch of nefarious pushers who pay off vulnerable doctors to prescribe their latest expensive, mediocre product," while still defending the special relationship that has developed between doctors and pharmaceutical manufacturers. However, Shaywitz's (2013) argument rests on opinion and conjecture rather than evidence.
Most established professional journals indicate that collusion between doctors and drug companies produces a range of problems that potentially harm patients. Writing for the British Medical Journal, Moynihan (2003) presents empirical evidence showing that doctors' prescribing habits change measurably after exposure to the skillful marketing techniques used by pharmaceutical industry representatives — techniques ranging from free dinners to gifts. Specifically, doctors' prescribing habits become "less appropriate" following such exposure, including "a rise in both prescription expenditures and irrational and incautious prescribing, according to a recent analysis of the ethics of gift giving" (Moynihan, 2003, p. 1189).
What is even more disturbing is that doctors appear to be unaware that their behavior changes as a result of pharmaceutical marketing. Moynihan (2003) found that doctors "deny their influence despite considerable evidence to the contrary" (p. 1189). Campbell (2007) also concluded that "physicians vehemently deny that their industry relationships have any of these negative effects," yet are ironically suspicious of their colleagues' ethical practices regarding pharmaceutical company payments. This denial is illustrated starkly in the Shaywitz (2013) piece for The Atlantic, in which the author claims that physician consultants for drug companies are sought out because they are "the smartest scientists or the most experienced clinicians." This assessment is misleading. Drug companies seek out physicians who are amenable to working with them and susceptible to direct marketing. Pharmaceutical manufacturers are driven by profit, and they would not invest in physicians whose integrity might interfere with that goal.
Physician denial makes it considerably harder to influence public policy on this issue, particularly because doctors occupy a high-status position in society and wield considerable political clout. Currently, it is perfectly legal for doctors to accept gifts — effectively bribes — from pharmaceutical representatives. A recent law attempts to introduce greater transparency by requiring manufacturers to disclose the amounts of money given to physicians, including free dinners and gifts (Campbell, 2007). This so-called Sunshine Law is bundled with the Affordable Care Act. However, the disclosure requirements apply only to companies with revenues exceeding $100 million and do not cover the delivery of free drug samples, which constitute a significant portion of pharmaceutical marketing. Because many pharmaceutical giants operate through subsidiaries, this law is unlikely to have meaningful impact on industry practices.
Moreover, disclosure alone does nothing to stop the practice. As reported in The Economist, the Sunshine Law may actually benefit pharmaceutical companies by providing them with a publicly available — and therefore cost-free — source of marketing data, allowing them to track per-doctor expenditures alongside per-patient prescription data to identify causal relationships between marketing methods and sales ("Let the Sunshine In," 2013). Removing the veil of secrecy from these arrangements is a step toward ethical transparency, but it is as halfhearted a measure as much of the Affordable Care Act.
You’re 48% through this paper. Sign up to read the remaining 3 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.